Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Overview

The study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate cancer.

Full Title of Study: “Randomized Phase II Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2025

Detailed Description

This study is a randomized non-inferiority trial comparing 5 to 2 radiotherapy treatments using an MRI linear accelerator for men with low or intermediate-risk prostate cancer electing for definitive radiotherapy.

Interventions

  • Radiation: Radiation Therapy
    • Eligible subjects will be randomly assigned to 5 or 2 fraction treatment groups in a 1:1 ratio using a computer-generated randomization scheme. After consent and eligibility verification, patients will undergo CT/MRI simulation and radiotherapy planning. Patients will receive treatment to the prostate +/- seminal vesicles per treating physician’s discretion in either 37.5 Gy in 5 fractions or 25 Gy in 2 fractions. SIB use is at treating physician’s discretion and should be concordant with imaging and biopsy findings with no PTV expansion. Subjects on 5 fraction arm should be treated on non-consecutive days. Subjects on the 2 fraction arm must have >72 hours between beginning of each fraction.

Arms, Groups and Cohorts

  • Experimental: 5 radiation treatments – ARM 1
    • Patients randomized to ARM 1 will receive 37.5 in 5 radiotherapy treatments.
  • Active Comparator: 2 radiation treatments – ARM 2
    • Patients randomized to ARM 2 will receive 25 Gy in 2 radiotherapy treatments.

Clinical Trial Outcome Measures

Primary Measures

  • Change in the number of patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)
    • Time Frame: Baseline, 24 months
    • The primary objective is to demonstrate that 2 treatments of radiotherapy does not significantly increase patient-reported Gastrointestinal (GI) and Genitourinary (GU) symptoms compared to 5 treatments of radiotherapy 2 years after treatment completion.

Secondary Measures

  • Change in the number of patient reported GI symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)
    • Time Frame: Baseline, 1 week , 3months, 6 months, 12 months and 60 months
    • Compare patient-reported GI symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment. Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes. Adverse events can be unexpected or expected, related to treatment.
  • Change in the number of patient reported GU symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)
    • Time Frame: Baseline, 1 week, 3months, 6 months, 12 months and 60 months
    • Compare patient-reported GU symptoms using the EPIC at end of RT and 3, 6, 12, and 60 months from end of treatment. Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes. Adverse events can be unexpected or expected, related to treatment.
  • Change in the number of patient reported sexual symptoms at specific intervals as measured by Expanded Prostate Cancer Index Composite (EPIC)
    • Time Frame: Baseline, 1 week, 3months, 6 months, 12 months and 60 months
    • Compare patient-reported sexual symptoms using the EPIC at end of RT and 3, 6, 12, 24, and 60 months from end of treatment. Expanded Prostate Cancer Index Composite (EPIC) short form questionnaire. The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Scores range from 0 to 100, lower scores indicate worse outcomes and higher EPIC scores represent better outcomes. Adverse events can be unexpected or expected, related to treatment.
  • Time to Progression (TTP)
    • Time Frame: 3 months
    • Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).
  • Time to Progression (TTP)
    • Time Frame: 6 months
    • Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).
  • Time to Progression (TTP)
    • Time Frame: 12 months
    • Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).
  • Time to Progression (TTP)
    • Time Frame: 60 months
    • Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).
  • Compare Overall Survival Rates
    • Time Frame: 3 months
    • Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • Compare Overall Survival Rates
    • Time Frame: 6 months
    • Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • Compare Overall Survival Rates
    • Time Frame: 12 months
    • Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • Compare Overall Survival Rates
    • Time Frame: 60 months
    • Compare Overall Survival (OS) in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • prostate cancer specific survival
    • Time Frame: 3 months
    • compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • prostate cancer specific survival
    • Time Frame: 6 months
    • compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • prostate cancer specific survival
    • Time Frame: 12 months
    • compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.
  • prostate cancer specific survival
    • Time Frame: 60 months
    • compare prostate cancer specific survival in patients among the two arms, 37.5 Gy in 5 fractions and 25 Gy in 2 fractions.

Participating in This Clinical Trial

Inclusion Criteria

  • Men aged >=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines. Low risk subjects per NCCN guidelines require a high risk Decipher score (≥0.60). – ECOG 0 – 1 – IPSS < 18 – Ability to receive MRI-guided radiotherapy. – Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. – Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator. Exclusion Criteria:

  • Prior history of receiving pelvic radiotherapy. – Patient with history of inflammatory bowel disease. – Unilateral or bilateral hip replacements. – History of bladder neck or urethral stricture. – TURP < 6 months prior to radiotherapy – Metastatic (pelvic nodal or distant) disease on CT, Bone, Fluciclovine, and/or PSMA PET scan

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Weill Medical College of Cornell University
  • Collaborator
    • Viewray Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Himanshu Nagar, M.D., Principal Investigator, Weill Medical College of Cornell University
  • Overall Contact(s)
    • Pragya Yadav, Ph.D, 6469622196, pry2003@med.cornell.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.